Komori
Changes in Officers7096StemCell InstituteInformation and Communications, Services and Others

Notice Regarding Changes in Directors and Executive Officers

Effective 1 August 2026, Kayano Kei (茅野 圭) will concurrently serve as Head of the Corporate Administration Division, while Tani Katsuhiro (谷 勝弘) will change from responsibility for the Corporate Administration Division to responsibility for major regional accounts and the Tokyo metropolitan area in the Sales Division. These are changes to the responsibilities of directors and executive officers, and do not involve departures or changes in appointees.

Worth reading
21Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Incoming appointee

1 item
Scheduled Appointment Date1 August 2026
Names of new appointees
Previous positionPrevious positions of appointees
New positionKayano Kei (茅野 圭): Director, Executive Officer, CFO, Head of the Corporate Administration Division / Tani Katsuhiro (谷 勝弘): Executive Officer, Sales Division, Major Regional Accounts and Tokyo Metropolitan Area
Reason for change

To strengthen the organizational structure of the Sales Division

Who is moving to which position
ItemDetails
Scheduled Appointment Date1 August 2026
Name of appointeeNames of new appointees
Appointee's new positionKayano Kei (茅野 圭): Director, Executive Officer, CFO, Head of the Corporate Administration Division / Tani Katsuhiro (谷 勝弘): Executive Officer, Sales Division, Major Regional Accounts and Tokyo Metropolitan Area
Appointee's previous positionPrevious positions of appointees
Reason for changeTo strengthen the organizational structure of the Sales Division
Items this document does not state (16)
Resolution dateDate of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To strengthen the organizational structure of the Sales Division.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Changes in Directors and Executive Officers | StemCell Institute (7096) timely disclosure | Komori